Avalo Therapeutics, Inc. business relationships
Companies named in Avalo Therapeutics, Inc.’s 10-K filed 2026-03-23, and public companies whose annual reports name Avalo Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Avalo Therapeutics, Inc.’s annual report 6
“...on upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine ("J&J") (the "AVTX-501 Milestone") and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreemen...” SEC filing
“The Company initially in-licensed the compound from an affiliate of Merck & Co., Inc. in 2013.” SEC filing
“• The Lilly License Agreement; and” SEC filing
“On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. ("KKC") for exclusive worldwide rights to develop, manufacture and commercialize quisovalimab, KKC's first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the "KKC License Ag...” SEC filing
“On May 28, 2021, the Company out-licensed its rights in respect of its non-core asset, AVTX-301, to Alto Neuroscience, Inc. ("Alto").” SEC filing
“Abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company ("Lilly") (the "Lilly License Agreement"), as well as an agreement under which AlmataBio, Inc. ("AlmataBio") purchased rights to the compound from Leap Therapeutics, Inc. ("Leap" and the "Leap Agreement").” SEC filing
Companies whose annual reports name Avalo Therapeutics, Inc. 1
“...n May 2021, we entered into a patent and know-how license agreement, or the Cerecor Agreement, with Cerecor Inc. (n/k/a Avalo Therapeutics, Inc.), or Cerecor, pursuant to which we obtained an exclusive worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights and...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.